Search Within

Jasmeet Chadha Singh

Formats
  1. Meeting Abstract (12)
  2. Journal Article (8)
  3. Review (2)
  4. Book Section (1)
Groups
  1. Breast Medicine Service (23)
  2. Department of Medicine (23)
  3. Solid Tumor Oncology Division (23)
  4. Survivorship Research (18)
  5. Population Sciences Research Program (15)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (13)

More Groups

People
  1. Chau Dang (15)
  2. Larry Norton (13)
  3. Clifford Hudis (10)
  4. Diana Lake (9)
  5. Jose Baselga (9)
  6. Lillian Smyth (9)

More People

Years
  1. 2024 (2)
  2. 2023 (1)
  3. 2022 (1)
  4. 2021 (2)
  5. 2020 (2)
  6. 2019 (3)

More Years

Publications
  1. Cancer Research (5)
  2. Journal of Clinical Oncology (4)
  3. The Oncologist (3)
  4. Annals of Oncology (2)
  5. Drugs & Aging (2)
  6. Expert Opinion on Drug Metabolism and Toxicology (2)

More Publications

Publishers
  1. American Association for Cancer Research (5)
  2. Oxford University Press (5)
  3. American Society of Clinical Oncology (4)
  4. Adis International Ltd (2)
  5. Informa Healthcare (2)
  6. Springer (2)

More Publishers

Results (23)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase Ib/II study of capecitabine 7/7 schedule with neratinib in patients with HER2-positive metastatic breast cancer (MBC)
    Meeting Abstract

    Wang, R.; Singh, J.; Sterlin, V.; Goldstein, M.; Lake, D.; Wong, S.; Baselga, J.; Norton, L.; Dang, C.
    Cancer Research (2019)

    Fulltext@MSK | Save
  • In reply
    Journal Article

    Dang, C. T.; Singh, J. C.; Steingart, R. M.; Yu, A. F.
    The Oncologist (2018)

    Fulltext@MSK | Save
  • Phase II study of gemcitabine (G), trastuzumab (H), and pertuzumab (P) for HER2-positive metastatic breast cancer (MBC) after prior pertuzumab-based therapy
    Meeting Abstract

    Iyengar, N. M.; Smyth, L. M.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; DeFusco, P. A.; Dickler, M. N.; Fornier, M. N.; Goldfarb, S. B.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy
    Meeting Abstract

    Iyengar, N. M.; Smyth, L. M.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; Defusco, P.; Dickler, M. N.; Fornier, M. N.; Goldfarb, S. B.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Cardiac safety of dual anti-HER2 therapy in the neoadjuvant setting for treatment of HER2-positive breast cancer
    Journal Article

    Yu, A. F.; Singh, J. C.; Wang, R.; Liu, J. E.; Eaton, A.; Oeffinger, K. C.; Steingart, R. M.; Hudis, C. A.; Dang, C. T.
    The Oncologist (2017)

    Fulltext@MSK | Save
  • Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-Positive metastatic breast cancer after prior pertuzumab-based therapy
    Meeting Abstract

    Iyengar, N. M.; Smyth, L.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; DeFusco, P.; Dickler, M. N.; Fornier, M. N.; Goldfarb, S.; more...
    Cancer Research (2017)

    Fulltext@MSK | Save
  • Pathologic complete response with neoadjuvant doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab and pertuzumab in patients with HER2-positive early stage breast cancer: A single center experience
    Journal Article

    Singh, J. C.; Mamtani, A.; Barrio, A.; Morrow, M.; Sugarman, S.; Jones, L. W.; Yu, A. F.; Argolo, D.; Smyth, L. M.; Modi, S.; more...
    The Oncologist (2017)

    Fulltext@MSK | Save
  • Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy
    Meeting Abstract

    Iyengar, N. M.; Smyth, L.; Lake, D.; Gucalp, A.; Singh, J.; Traina, T. A.; Defusco, P.; Dickler, M. N.; Fornier, M.; Goldfarb, S.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Activity of HP-based therapies as third and later lines for the treatment of HER2-positive metastatic breast cancer: A retrospective study from a single institution
    Meeting Abstract

    Argolo, D.; Friedman, M.; Smyth, L.; Iyengar, N.; Singh, J.; Patil, S.; Norton, L.; Baselga, J.; Hudis, C.; Dang, C.
    Cancer Research (2016)

    Fulltext@MSK | Save
  • Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: Overall survival and updated progression-free survival results from a phase II study
    Journal Article

    Smyth, L. M.; Iyengar, N. M.; Chen, M. F.; Popper, S. M.; Patil, S.; Wasserheit-Lieblich, C.; Argolo, D. F.; Singh, J. C.; Chandarlapaty, S.; Sugarman, S. M.; more...
    Breast Cancer Research and Treatment (2016)

    Fulltext@MSK | Save